Novel alginate-enclosed chitosan-calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy

Nanomedicine

Volumn 7, Issue 10, 2012, Pages 1521-1550

  Kanwar, Jagat R ^a   Mahidhara, Ganesh ^a   Kanwar, Rupinder K ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

alginate; anticancer protein; ceramic nanocore; chitosan; endocytosis; iron saturated bovine lactoferrin; nanocarrier; oral drug delivery; transcytosis; xenograft

Indexed keywords

ALGINIC ACID; CALCIUM; CALCIUM PHOSPHATE; CHITOSAN; IRON; LACTOFERRIN; NANOCARRIER; PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; COLON CANCER; CONTROLLED STUDY; DIET; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; ENDOCYTOSIS; FEMALE; GELATION; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; MOUSE; NANOPRECIPITATION; NONHUMAN; ORGAN WEIGHT; PRECIPITATION; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSCYTOSIS; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ALGINATES; ANIMALS; ANTINEOPLASTIC AGENTS; CALCIUM PHOSPHATES; CATTLE; CHITOSAN; COLONIC NEOPLASMS; ENDOCYTOSIS; GLUCURONIC ACID; HEXURONIC ACIDS; HUMANS; IRON; LACTOFERRIN; MICE; NANOPARTICLES; PACLITAXEL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869406664     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.29     Document Type: Article

References (40)

1. Brazeau P, Vale W, Burgus R et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179(4068), 77-79 (1973).
2. Burke PG, Li Q, Costin ML, Mcmullan S, Pilowsky PM, Goodchild AK. Somatostatin 2A receptor-expressing presympathetic neurons in the rostral ventrolateral medulla maintain blood pressure. Hypertension 52(6), 1127-1186 (2008).
3. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat. Rev. Drug Discov. 2(12), 999-1017 (2003).
4. Draznin B, Sherman N, Sussman K, Dahl R, Vatter A. Internalization and cellular processing of somatostatin in primary culture of rat anterior pituitary cells. Endocrinology 117(3), 960-966 (1985).
5. Viguerie N, Esteve JP, Susini C, Vaysse N, Ribet A. Processing of receptor-bound somatostatin: Internalization and degradation by pancreatic acini. Am. J. Physiol. Gastrointest. Liver Physiol. 252(4), G535-G542 (1987).
6. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc. Natl Acad. Sci. USA 89(1), 251-255 (1992).
7. Feindt J, Becker I, Blömer U et al. Expression of somatostatin receptor subtypes in cultured astrocytes and gliomas. J. Neurochem. 65(5), 1997-2005 (1995).
8. Breeman WAP, De Jong M, Kwekkeboom DJ et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur. J. Nucl. Med. 28(9), 1421-1429 (2001).
9. Slooter GD, Mearadji A, Breeman WA et al. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours. Br. J. Surg. 88(1), 31-40 (2001).
10. Jakobs KH, Schultz G. Occurrence of a hormone-sensitive inhibitory coupling component of the adenylate cyclase in S49 lymphoma cyc-variants. Proc. Natl Acad. Sci. USA 80(13), 3899-3902 (1983).
11. Pennefather PS, Heisler S, Macdonald JF. A potassium conductance contributes to the action of somatostatin-14 to suppress ACTH secretion. Brain Res. 444(2), 346-350 (1988).
12. Akbar M, Okajima F, Tomura H et al. Phospholipase-C activation and Ca2+ mobilization by cloned human somatostatin receptor subtypes-1-5, in transfected Cos-7 cells. FEBS Lett. 348(2), 192-196 (1994).
13. Cescato R, Schulz S, Waser B et al. Internalization of sst(2), sst(3), and sst(5) receptors: effects of somatostatin agonists and antagonists. J. Nucl. Med. 47(3), 502-511 (2006).
14. Liu QS, Cescato R, Dewi DA, Rivier J, Reubi JC, Schonbrunn A. Receptor signaling and endocytosis are differentially regulated by somatostatin analogs. Mol. Pharmacol. 68(1), 90-101 (2005).
15. Koenig JA, Kaur R, Dodgeon I, Edwardson JM, Humphrey PP. Fates of endocytosed somatostatin sst(2) receptors and associated agonists. Biochem. J. 336(Pt 2), 291-298 (1998).
16. Hipkin RW, Friedman J, Clark RB, Eppler CM, Schonbrunn A. Agonist-induced desensitization, internalization, and phosphorylation of the sst2A somatostatin receptor. J. Biol. Chem. 272(21), 13869-13876 (1997).
17. Kostenich G, Livnah N, Bonasera TA et al. Targeting small-cell lung cancer with novel fluorescent analogs of somatostatin. Lung Cancer 50(3), 319-328 (2005).
18. Becker A, Hessenius C, Licha K et al. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat. Biotechnol. 19(4), 327-331 (2001).
19. Sreenivasan VKA, Stremovskiy OA, Kelf TA et al. Pharmacological characterization of a recombinant, fluorescent somatostatin receptor agonist. Bioconjug. Chem. 22(9), 1768-1775 (2011).
20. Sarret P, Nouel D, Dal Farra C, Vincent JP, Beaudet A, Mazella J. Receptor-mediated internalization is critical for the inhibition of the expression of growth hormone by somatostatin in the pituitary cell line AtT-20. J. Biol. Chem. 274(27), 19294-19300 (1999).
21. Waser B, Tamma ML, Cescato R, Maecke HR, Reubi JC. Highly efficient in vivo agonist-induced internalization of sst(2) receptors in somatostatin target tissues. J. Nucl. Med. 50(6), 936-941 (2009).
22. Chan WCW, Nie SM. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 281(5385), 2016-2018 (1998).
23. Bruchez M, Moronne M, Gin P, Weiss S, Alivisatos AP. Semiconductor nanocrystals as fluorescent biological labels. Science 281(5385), 2013-2016 (1998).
24. Heer S, Lehmann O, Haase M, Gudel HU. Blue, green, and red upconversion emission from lanthanide-doped LuPO4 and YbPO4 nanocrystals in a transparent colloidal solution. Angew. Chem. Int. Ed. Engl. 42(27), 3179-3182 (2003).
25. Sreenivasan VKA, Ivukina EA, Deng W et al. Barstar:barnase - a versatile platform for colloidal diamond bioconjugation. J. Mater. Chem. 21(1), 65-68 (2011).
26. Alivisatos AP. Semiconductor clusters, nanocrystals, and quantum dots. Science 271(5251), 933-937 (1996).
27. Green N. Avidin. Adv. Protein Chem. 29, 85-133 (1975).
28. Zdobnova TA, Dorofeev SG, Tananaev PN et al. Fluorescent immunolabeling of cancer cells by quantum dots and antibody scFv fragment. J. Biomed. Opt. 14(2), 021004 (2009).
29. Gruber HJ, Marek M, Schindler H, Kaiser K. Biotin-fluorophore conjugates with poly(ethylene glycol) spacers retain intense fluorescence after binding to avidin and streptavidin. Bioconjug. Chem. 8(4), 552-559 (1997).
30. Patel YC, Panetta R, Escher E, Greenwood M, Srikant CB. Expression of multiple somatostatin receptor genes in AtT-20 cells - Evidence for a novel somatostatin-28 selective receptor subtype. J. Biol. Chem. 269(2), 1506-1509 (1994).
31. Kelf TA, Sreenivasan VKA, Sun J, Kim EJ, Goldys EM, Zvyagin AV. Non-specific cellular uptake of surface-functionalized quantum dots. Nanotechnology 21(28), 285105 (2010).
32. Howarth M, Takao K, Hayashi Y, Ting AY. Targeting quantum dots to surface proteins in living cells with biotin ligase. Proc. Natl Acad. Sci. USA 102(21), 7583-7588 (2005).
33. Alon R, Bayer EA, Wilchek M. Streptavidin contains an RYD sequence which mimics the RGD receptor domain of fibronectin. Biochem. Biophys. Res. Commun. 170(3), 1236-1241 (1990).
34. Lelouvier B, Tamagno G, Kaindl AM et al. Dynamics of somatostatin type 2A receptor cargoes in living hippocampal neurons. J. Neurosci. 28(17), 4336-4349 (2008).
35. Grant M, Collier B, Kumar U. Agonist-dependent dissociation of human somatostatin receptor 2 dimers - a role in receptor trafficking. J. Biol. Chem. 279(35), 36179-36183 (2004).
36. Grant M, Kumar U. The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. Regul. Pept. 159(1-3), 3-8 (2010).
37. Swift JL, Burger MC, Massotte D, Dahms TE, Cramb DT. Two-photon excitation fluorescence cross-correlation assay for ligand-receptor binding: Cell membrane nanopatches containing the human mu-opioid receptor. Anal. Chem. 79(17), 6783-6791 (2007).
38. Jaiswal JK, Mattoussi H, Mauro JM, Simon SM. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat. Biotechnol. 21(1), 47-51 (2003).
39. Finn FM, Titus G, Hofmann K. Ligands for insulin receptor isolation. Biochemistry 23(12), 2554-2558 (1984).
40. Barbarakis MS, Daunert S, Bachas LG. Effect of different binding-proteins on the detection limits and sensitivity of assays based on biotinylated adenosine-deaminase. Bioconjug. Chem. 3(3), 225-229 (1992).